Improve access to PrEP for underserved communities in Rio de Janeiro

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The PrEPOUT Rio program uses a three-phase approach starting with formative qualitative work to identify local barriers and adapt community delivery strategies. In the implementation phase, trained staff will offer on-site HIV testing, counseling, and same-site PrEP initiation at community organizations, mobile health units, and through telehealth. Participants who test negative will be offered daily oral PrEP with mHealth follow-up and adherence support, while those testing positive will be referred for HIV treatment. An evaluation phase will measure uptake, retention, and feasibility of these community-based delivery models.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Individuals aged 15 years or older
* Gay, bisexual, and other men who have sex with men (MSM)
* Transgender women and travestis
* Other sexual and gender minorities (SGM)
* Cisgender women in situations of social or economic vulnerability
* Sex workers
* Individuals seeking HIV testing and/or pre-exposure prophylaxis (PrEP)
* HIV-negative at screening
* Willing and interested in initiating PrEP
* Eligible for PrEP according to Brazilian national guidelines

Exclusion Criteria:

* Positive HIV test result at screening or during study participation
* Individuals not eligible for PrEP according to Brazilian national guidelines

Where it's running

• Hospital Geral de Nova Iguaçu
  Nova Iguaçu, Rio de Janeiro, Brazil Recruiting
• Instituto Nacional de Infectologia Evandro Chagas
  Rio de Janeiro, Rio de Janeiro, Brazil Recruiting

Study contacts

• Study coordinator: Beatriz Grinsztejn
• Email: beatriz.grinsztejn@gmail.com
• Phone: +55 2138659128

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Camino HIV Prevention and Care Study

  This study tests a combined legal and peer-support program to help Latin American adults in DC and the Bay Area improve HIV testing, PrEP use, and care engagement.

  Recruiting American University · Berkeley, California and 1 other locations · NCT07834853

• VH4367310 in healthy adults: testing single increasing doses for safety and how it behaves in the body

  This study tests a single rising dose of VH4367310, a cabotegravir prodrug, to see how it behaves in the body and how safe and tolerable it is in healthy adults aged 18 to 55.

  Recruiting at 2 sites Phase 1 ViiV Healthcare · Glendale, California and 1 other locations · NCT07818915

• Online cohort of sexual and gender minorities testing digital support to boost PrEP and ART use

  In Brazil, sexually and gender diverse adults are being followed online to see if weekly WhatsApp reminders help people stick to PrEP or ART.

  Recruiting Oswaldo Cruz Foundation · Rio de Janeiro, Rio de Janeiro · NCT07772791

• Metabolic Liver Disease in People Newly Diagnosed with HIV

  This study tests whether HIV-infected adults who are starting ART are more likely to develop MASLD and related liver issues than HIV-negative adults over five years.

  Recruiting at 11 sites Guven Health Group · Ankara, Ankara and 10 other locations · NCT07737340

• Screen2Prevent: HIV screening for teens and young adults in emergency departments

  The study tests three ways of offering HIV screening to people aged 14–24 in emergency departments to see if it helps link them to PrEP or HIV treatment using digital health tools.

  Recruiting at 5 sites Westat · Tampa, Florida and 4 other locations · NCT07728123

• Long-acting LEN/TAB/ZAB vs CAB/RPV in adults with HIV-1 who are virologically suppressed on daily ART

  This study tests whether switching to a weekly-plus long-acting injectable regimen of lenacapavir, teropavimab, and zinlirvimab works as well as a two-drug injectable regimen of cabotegravir and rilpivirine for adults with HIV-1 who already have undetectable virus on daily treatment.

  Recruiting at 19 sites Phase 3 Gilead Sciences · San Francisco, California and 18 other locations · NCT07682961

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.